Search Results for: Eloxx Pharmaceuticals Announces First Patient
Articles
January 25, 2023
Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating Treatment for Alport Syndrome January 25, 2023
Eloxx Pharmaceuticals, Inc. recently announced the first patients have now been enrolled in its Phase 2 study of ELX-02 for...
December 4, 2017
Eloxx Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial December 4, 2017
Sevion Therapeutics, Inc. and Eloxx Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company developing novel translational read-through inducing drugs (TRIDs) for genetic...
July 10, 2023
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM Platform to Target the Human Ribosome for Therapeutic Benefit July 10, 2023
Eloxx Pharmaceuticals, Inc. recently announced that Cancer Research Communications has published A Novel Class of Ribosome Modulating Agents Exploits Cancer...
May 2, 2023
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013 May 2, 2023
Eloxx Pharmaceuticals, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application to initiate a...
